Ankündigung

Einklappen
Keine Ankündigung bisher.

Der Heisseste Biotech Wert der Dekade !

Einklappen
X
  • Filter
  • Zeit
  • Anzeigen
Alles löschen
neue Beiträge

  • Der Heisseste Biotech Wert der Dekade !

    Mai Edition newsletter sagt Sangamo ist der heisseste wert der decade

    [WIKI]nasdaq[/WIKI] SGMO

    History And Huge Gains
    In The Making
    Gene therapies are lighting up the
    world of biotech and this month’s
    recommendation is changing the game.
    They have built a history of firsts in the
    gene editing space and big pharma
    is lining up to use their one of a kind
    technology.

    hier das PDF https://www.investorvillage.com/uplo..._of_Decade.pdf

  • #2
    AW: Der Heisseste Biotech Wert der Dekade !

    Ohh! Ein sprechender Elch will meine Kreditkartennummer. Das klingt fair!

    [ame]https://www.youtube.com/watch?v=f0ca9wwkhDs[/ame]
    Disclaimer: Meine Beiträge sind nie Anlageberatung. Sie dienen der Diskussion.
    Portfolio: ADM | JNJ | JPM | KO | MMM | MO | PG | SNY | T | UN | WM | XOM

    Kommentar


    • #3
      AW: Der Heisseste Biotech Wert der Dekade !

      eine PDF will bestimmt nit irgentwas von dir

      Kommentar


      • #4
        AW: Der Heisseste Biotech Wert der Dekade !

        warte hier is noch ein anderer linl falls du keinen IV account hast ... http://bridgeandtunnelinvestor.com/t...ratings?page=2

        Kommentar


        • #5
          AW: Der Heisseste Biotech Wert der Dekade !

          Zitat von petterson Beitrag anzeigen
          eine PDF will bestimmt nit irgentwas von dir
          Nee, PDFs aus unbekannten Quellen sind total sicher
          Genauso sicher wie Anlagetips unter der Überschrift "heissester Wert der Dekade" von einem neu angemeldeten Nutzer. Geh woanders auf Deppensuche
          sigpic
          ”There’s class warfare, all right, but it’s my class, the rich class, that’s making war, and we’re winning.”
          W. Buffet

          Sommerzeit abschaffen

          Kommentar


          • #6
            AW: Der Heisseste Biotech Wert der Dekade !

            hab ich doch nicht geschrieben den artikel

            wie auch immer
            grade paper raus gekommen

            60% aller menschen sind imun gegen Cas9


            heißt kein in vivo gene editing möglich mit crispr

            gute zeit edit ntla und crsp [WIKI]short[/WIKI] zu gehen

            hier das release des papers

            https://www.biorxiv.org/content/early/2018/04/04/295139https://www.biorxiv.org/content/early/2018/04/04/295139

            Kommentar


            • #7
              AW: Der Heisseste Biotech Wert der Dekade !

              das ist ein link vom investor village board mit 400+ views ... wieso soll das nicht safe sein ?
              nur weil ich neu angemeldet bin bin ich virus verbreiter oder was ?

              check doch den link

              Kommentar


              • #8
                AW: Der Heisseste Biotech Wert der Dekade !

                Yup - geile Kiste!

                Ich kauf den ganzen Laden!

                Morgen sprech ich mit meiner Bank!

                Gold is the money of kings, silver is the money of gentlemen, barter is the money of peasants – but debt is the money of slaves. ...
                "Who the fuck is this guy 'Margin' that keeps calling me the whole day long?!"
                "Dumm ist der, der Dummes tut." Forrest Gump
                ~~ my-private-capital ~~

                Kommentar


                • #9
                  AW: Der Heisseste Biotech Wert der Dekade !

                  Forbes empfiehlt Sangamo SGMO zu kaufen , ultra bullisher report grade raus !

                  Sangamo Therapeutics is a leader in the development of gene editing, and gene and cell therapies based on their proprietary zinc finger nuclease (ZFN) technology platform. Sangamo is a classic biotech turnaround story as the company had a management overhaul in 2016 that has positioned the company for significant success. A great example is the recent partnership with Gilead Sciences/Kite Pharma. Despite being pre-clinical and early stage, Gilead is paying $150 million upfront in cash and up to $3.1 billion in milestones plus tiered royalties on ten Sangamo-derived cancer drug candidates (or $300 million per product). Combining the Kite, Gilead expertise and infrastructure with Sangamo will create a transformative leader in the field. The terms of this deal (like the Nektar Therapeutics/Bristol-Myers Squibb deal of late) are resetting the [WIKI]bar[/WIKI] higher for the growing value of truly novel products and technologies that biotechnology is creating – this time led by Sangamo.



                  Deal structure

                  Upfront: $150 million cash up front

                  Breadth: $3.1 billion in milestones/R&D or ~$300 million per product

                  Royalties: Tiered royalties on each product.

                  Sangamo’s significant progress outside of cancer has led to this deal. Sangamo’s ZFN and AAV technology is now applicable for off-the-shelf cancer therapies for both liquid and solid tumors – and Gilead Sciences/Kite Pharma is the best possible partner for many reasons. Gilead and Kite were sold by what Sangamo has done with its technology outside of oncology. Sangamo’s technology is developing the next generation of autologous CAR-T and T cell receptor (TCR) technology in a very broad array of virtually endless cancers. In our view, the potential to create off-the-shelf CAR-Ts is game-changing.

                  When Kite Pharma came looking for a gene-editing partner (a public goal of theirs), they chose Sangamo over all the others (Crispr Therapeutics, Editas Medicine, etc.). That in and of itself, says a lot about the strength of Sangamo’s platform.

                  More Sangamo deals coming in more therapeutic areas. In addition to oncology, the breadth of the Sangamo technology is and will develop more gene therapy/editing in vivo in various tissue types.

                  This will result in additional partnerships and Sangamo will do their own where they can (Orphan/rare diseases).

                  Nononcology gene therapy medicines in other areas such as autoimmune.
                  Clinical Trials Underway – Data From Two Trials By Mid-Year

                  SB-913 – MPS II – CHAMPIONS Study – preliminary data mid-2018

                  SB-318 – MPS I – 5 sites screening

                  SB-FIX – 4 active sites; slower enrollment

                  SB-525 – Top line sometime mid-2018 – Scientific Meeting Hem. A (with partner PFE)

                  ST-400 – beta thal – ex vivo-non-viral approach may be an advantage over lenitiviral (e.g., BLUE) – filed IND, sites open, first date treated by mid-2018

                  We have known and followed Sangamo for a very [WIKI]long[/WIKI] time. The details of the Gilead/Kite deal and the ongoing progress in their patented ZFN technologies are at last opening the visibility of the vast potential to Wall Street. The management team at Sangamo is truly impressive and continues to grow as they attract seasoned executives on a global basis. In our view, they are the underrecognized leader in the gene editing and therapy field and we expect a steady stream of clinical and strategic announcements going forward that will serve as positive stock catalysts.


                  https://www.forbes.com/sites/moneysh...four-horsemen/

                  Kommentar


                  • #10
                    AW: Der Heisseste Biotech Wert der Dekade !

                    Wenn ich mir den [WIKI]Chart[/WIKI] anschaue, ist die Info bei noch nicht sehr vielen Leuten angekommen. Hat in den letzten 2 Wochen von 27 usd auf 17 usd korrigiert.

                    Kommentar


                    • #11
                      AW: Der Heisseste Biotech Wert der Dekade !

                      Zitat von EinSportfreund Beitrag anzeigen
                      Wenn ich mir den Chart anschaue, ist die Info bei noch nicht sehr vielen Leuten angekommen. Hat in den letzten 2 Wochen von 27 usd auf 17 usd korrigiert.
                      DArum ist es doch der heisseste Wert der Dekade, kauf schnell, bevor es alle mitbekommen und der Kurs explodiert! Am Besten, per Hypothek aufs Haus
                      sigpic
                      ”There’s class warfare, all right, but it’s my class, the rich class, that’s making war, and we’re winning.”
                      W. Buffet

                      Sommerzeit abschaffen

                      Kommentar


                      • #12
                        AW: Der Heisseste Biotech Wert der Dekade !

                        naja wenn ihr nicht wollt ... müsst ja nicht ....

                        Kommentar


                        • #13
                          AW: Der Heisseste Biotech Wert der Dekade !

                          FOOL grade raus:

                          Biotech Fire Sale: 2 Top Stocks to Buy Next Week

                          SGMO Get in on the ground floor

                          Sangamo's stock has been red-hot over the past 12 months due to the growing interest in all-things gene therapy. The backstory is that Sangamo struck a series of licensing deals with biopharma heavyweights Gilead Sciences (NASDAQ:GILD) and Pfizer (NYSE:PFE) to develop next-generation therapies for cancer and rare diseases like the bleeding disorder hemophilia.

                          The Gilead partnership centers around creating adoptive cell therapies that can be manufactured at scale using Sangamo's zinc-finger nuclease (ZFN) gene-editing platform. The current generation of adoptive cell therapies require extensive manufacturing processes that can delay treatment, and create backlogs of patients.

                          That being said, Gilead's decision to tap Sangamo's ZFN platform did surprise most Wall Street analysts and industry insiders. The consensus was that Gilead would ultimately go the CRISPR route for its gene-editing needs. After all, Sangamo's ZFN platform is more labor-intensive and time-consuming than CRISPR. With serious questions currently swirling around CRISPR's safety in human subjects, however, Sangamo's ZFN tech was apparently the more compelling choice for Gilead at this stage in the game.

                          The big ticket item for investors here is that this gene-editing deal with Gilead could eventually translate into a whopping $3 billion in total milestone payments for Sangamo -- that is, if things go according to plan. That's a staggering opportunity for a company with a market cap of less than half that amount at present.

                          Sangamo's severe hemophilia A partnership with Pfizer is also on track to produce preliminary data by mid-year. If successful, this partnership may trigger buyout talks between the two companies. Pfizer, after all, has deep interests in novel treatments for rare diseases, and the biopharma is currently in the process of ramping up its adoptive cell therapy pipeline as well. Put simply, Sangamo would be a near-perfect fit for Pfizer.

                          Aside from the possibility of a buyout from one of its partners, Sangamo's deep and robust gene therapy platform also offers up another compelling reason to own this stock right now. Sangamo could run into some bad luck in the clinic, but the sheer breadth of its cutting-edge pipeline should ultimately land the company a commercial-stage product at some point.

                          So, like its clinical-stage peer Jounce, Sangamo's risk-to-reward ratio is arguably heavily skewed toward the upside as things stand now. The biotech's 10.8% drop last week therefore comes across as an incredible buying opportunity for investors with a long-term mind-set.

                          https://www.fool.com/investing/2018/...next-week.aspx

                          Kommentar


                          • #14
                            AW: Der Heisseste Biotech Wert der Dekade !

                            Kommentar


                            • #15
                              AW: Der Heisseste Biotech Wert der Dekade !

                              Sehr fleißig, was Du hier machst und hast trotzdem noch die Zeit, negative pöngs zu verteilen, es wird immer seriöser! Ich nehme an, in spätestens zwei Wochen schickst Du ein Bild von Deinem Anwesen auf den Bahamas, das Du mit dem Börsengewinn gekauft haben wirst.
                              sigpic
                              ”There’s class warfare, all right, but it’s my class, the rich class, that’s making war, and we’re winning.”
                              W. Buffet

                              Sommerzeit abschaffen

                              Kommentar

                              Lädt...
                              X